Natural history of Acinetobacter baumannii infection in mice
Open Access
- 18 July 2019
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (7) , e0219824
Abstract
In 2017, the WHO identified Acinetobacter baumannii as the top priority for the development of new antibiotics. Despite the need for new antibiotics, there remains a lack of well validated preclinical tools for A. baumannii. Here, we characterize and validate a mouse model for A. baumannii translational research. Antibiotic sensitivity for meropenem, amikacin, and polymyxin b was determined by the broth microdilution MIC assay. LD100 inoculums, in both blood and lung infection models, were determined in male and female C3HeB/FeJ mice that were challenged with various A. baumannii clinical isolates. Blood (blood infection model) or blood and lung tissue (lung infection model) were collected from infected mice at 2 and 18 hours and the bacterial burden was determined by quantitative culture. Blood chemistry was analyzed using the iStat system. Cytokines (IL-1ß, TNF, IL-6, and IL-10) were measured in the blood and lung homogenate by ELISA assay. Lung sections (H&E stains) were scored by a pathologist. In the blood infection model, the cytokines and physiological data indicate that mice become moribund due to sepsis (low blood pH, falling bicarbonate, and a rising base deficit), whereas mice become moribund due to respiratory failure (low blood pH, rising bicarbonate, and a falling base deficit) in the oral aspiration pneumonia model. We also characterized the timing of changes in various clinical and biomarker endpoints, which can serve as a basis for future interventional studies. Susceptibility was generally similar across gender and infection route. However, we did observe that female mice were approximately 2-fold more sensitive to LAC-4 ColR in the blood infection model. We also observed that female mice were more than 10-fold more resistant to VA-AB41 in the oral aspiration pneumonia model. These results establish parameters to follow in order to assess efficacy of novel preventative and therapeutic approaches for these infections.Keywords
This publication has 18 references indexed in Scilit:
- Nosocomial Acinetobacter pneumonia: Treatment and prognostic factors in 356 casesRespirology, 2015
- Cryopreservation of virulent Acinetobacter baumannii to reduce variability of in vivo studiesBMC Microbiology, 2015
- Risk factors for and impact of carbapenem-resistant Acinetobacter baumannii colonization and infection: matched case–control studyEuropean Journal of Clinical Microbiology & Infectious Diseases, 2015
- Host Fate is Rapidly Determined by Innate Effector-Microbial Interactions During Acinetobacter baumannii BacteremiaThe Journal of Infectious Diseases, 2014
- Evaluation of the Trimeric Autotransporter Ata as a Vaccine Candidate against Acinetobacter baumannii InfectionsInfection and Immunity, 2012
- The virulence variability of different Acinetobacter baumannii strains in experimental pneumoniaJournal of Infection, 2010
- Intratracheal colistin sulfate for BALB/c mice with early pneumonia caused by carbapenem-resistant Acinetobacter baumanniiCritical Care Medicine, 2009
- Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2009
- Antimicrobial Resistance:Acinetobacter baumannii:Epidemiology, Antimicrobial Resistance, and Treatment OptionsClinical Infectious Diseases, 2008
- Neutrophils Play an Important Role in Host Resistance to Respiratory Infection with Acinetobacter baumannii in MiceInfection and Immunity, 2007